TG Therapeutics

J.P. Morgan Healthcare Conference

TG Therapeutics (NASDAQ: TGTX)

Presenter: Michael S. Weiss, Chairman & CEO

January 2026

Forward Looking Safe Harbor Statement

This presentation contains forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.

Such forward looking statements include but are not limited to statements regarding the estimated preliminary financial results referred to above, expectations for the timing and success of the commercialization and availability of BRIUMVI® (ublituximab-xiiy) for relapsing forms of multiple sclerosis (RMS) in the United States, or any jurisdictions outside of the United States; anticipated healthcare professional (HCP) and patient acceptance and use of BRIUMVI for the approved indications; expectations of future revenue for BRIUMVI, or our expenses or profit estimates or targets; our ability to execute the proposed share repurchase program; expectations and timing for our clinical trials of subcutaneous ublituximab (the active ingredient in BRIUMVI), and sometimes referred to as subcutaneous BRIUMVI, including feasibility, approvability and commercial acceptance; expectations and timing for our ENHANCE Phase 3 trial combining day 1 and day 15 doses, including, feasibility, approvability and commercial acceptance and impact on BRIUMVI sales; and expectations and timing for any of our pipeline products or programs, including Azer-cel or BRIUMVI in MG.

Additional factors that could cause our actual results to differ materially include the following: the Company's ability to continue to commercialize BRIUMVI; the risk that trends in prescriptions are not maintained or that prescriptions are not filled; the failure to obtain and maintain payor coverage; the risk that HCP interest in BRIUMVI will not be sustained; the risk that momentum in sales for BRIUMVI will not be sustained during the course of the year; the risk that the commercialization of BRIUMVI does not continue to exceed expectations; the risk that our BRIUMVI revenue targets will not be achieved; the failure to obtain and maintain requisite regulatory approvals, including the risk that the Company fails to satisfy post-approval regulatory requirements, the potential for variations from the Company's projections and estimates about the potential market for BRIUMVI due to a number of factors, including, further limitations that regulators may impose on the required labeling for BRIUMVI (such as modifications, resulting from safety signals that arise in the post-marketing setting or in the long-term extension study from the ULTIMATE I and II clinical trials); the Company's ability to meet post-approval compliance obligations (on topics including but not limited to product quality, product distribution and supply chain, pharmacovigilance, and sales and marketing); the Company's reliance on third parties for manufacturing, distribution and supply, and other support functions for our clinical and commercial products, including BRIUMVI, and the ability of the Company and its manufacturers and suppliers to produce and deliver BRIUMVI to meet the market demand for BRIUMVI; the risk that any individual patient's clinical experience in the post-marketing setting, or the aggregate patient experience in the post-marketing setting, may differ from that demonstrated in controlled clinical trials such as ULTIMATE I and II; the risk that the Company does not achieve its 2026 development pipeline anticipated milestones or goals in the timeframe projected or at all; the risk that the subcutaneous Phase 3 program will not be successful or if successful still will not be approved by the FDA or achieve commercial acceptance; the risk that the ENHANCE Phase 3 trial will not be successful or if successful will not be approved by the FDA or achieve commercial acceptance; the risk that we will not move forward with the development of BRIUMVI in MG and azer-cel following these preliminary studies; the uncertainties generally inherent in research and development; regulatory developments, legislative actions, executive orders, including the imposition of tariffs and policy changes in the U.S. and other jurisdictions; and general political, economic and business conditions.

The preliminary, estimated financial results for the fourth quarter and fiscal year ended 2025 and the 2026 guidance estimates provided in this presentation contain forward-looking statements and are subject to the completion of management's and the audit committee's final reviews and our other financial closing procedures and are therefore subject to change.

Further discussion about these and other risks and uncertainties can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and in our other filings with the U.S. Securities and Exchange Commission. Any forward-looking statements set forth in this presentation speak only as of the date of this presentation. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.

TG Therapeutics Background

Founded in 2012 with a focus on developing treatments for people with B-cell mediated diseases

1 Approved Drug Approaching Blockbuster Status

2 Pivotal Trials Ongoing to Expand Total Addressable Market

3 Programs Under Development

BRIUMVI: The first & only anti-CD20 for RMS delivered in a 1-hour infusion every 6 months after starting dose

Approved in the U.S. for Adults with Relapsing forms of Multiple Sclerosis - Launched Jan 29, 2023

BRIUMVI is Rapidly Becoming a Global Brand

Partner-led commercialization across EU and ROW

16

countries outside the U.S. where BRIUMVI has already launched

20,000+

patients prescribed BRIUMVI worldwide[1]

TG Therapeutics

1: TG and NXP internal estimates

Anti-CD20s Are the Standard in MS —

Capturing ~50% of Dynamic and Overall Market Share[1]

~$10B and Growing Anti-CD20 Market in the U.S. Today[2]

Three (3) Anti-CD20's Approved for MS, Including BRIUMVI

Anti-CD20 U.S. Dynamic Market Share[3]



Two (2) HCP Administered Options, including BRIUMVI
One (1) Patient Administered Option

TG Therapeutics

1: Q3'25 Komodo Claims; 2:Publicly available company earnings calls and filings; 2 3: Q1'25 – Q3'25 Komodo Claims; HCP: healthcare professional

Our Goal is to be the #1 Prescribed Anti-CD20 in RMS Based on Dynamic Market Share

BRIUMVI has Seen Significant Uptake in the HCP Administered Anti-CD20 MS Market in <3 Years

>97%

of Top 200 MS Centers Using BRIUMVI[1]

~90%

of High Decile HCPs Prescribing BRIUMVI[2]

~1/3

of HCP Administered Anti-CD20 Dynamic Market[3]

~20%

Dynamic Anti-CD20 Share[3]

1: TG Patient Support HUB enrollments and TG shipment data; 2: TG Patient Support HUB enrollments and TG internal HCP deciling (includes deciles 8-10 which captures HCPs who drive top 30% of CD20 market opportunity based on internal TG ranking 3: TG Internal Estimates

Nearing $1B in Cumulative BRIUMVI US Revenue

~$992M
Cumulative BRIUMVI U.S. Net Revenue LTD[1]

~$616M
Total Global Revenue FY 2025[1]

~$594M
BRIUMVI U.S. Net Revenue FY 2025[1]

~90% growth FY24 vs.FY25

~$182M
BRIUMVI U.S. Net Revenue Q4 2025[1]

~20% growth Q3'25 vs.Q4'25



TG Therapeutics

1. Q4 2025, FY 2025 and cumulative figures included are preliminary, unaudited, subject to adjustment, and provided as an approximation in advance of the Company's announcement of complete financial results; YoY: Year over Year; Q4: Fourth Quarter; FY: Full Year; LTD: Launch to date

BRIUMVI Differentiation

The first & only anti-CD20 for RMS delivered in a 1-hour infusion every 6 months after starting dose

PRODUCT

Consistent efficacy and safety over 6 years (ARR 0.012)[1]

Label without breast cancer risk and colitis[2]

Glycoengineered for enhanced ADCC

PEOPLE

Highly experienced commercial and medical teams

Average 12 years of MS experience

Focused on customer service

PRICE

Lowest priced branded MS treatment[3]

Potential for significant savings to the healthcare system[4]

Lowest priced and the preferred anti-CD20 for VA

TG Therapeutics

1: BRIUMVI® (ublituximab-xiiy) Phase 3 open-label extension (OLE) study, 6-year follow-up ; 2: BRIUMVI® (ublituximab-xiiy) U.S. Prescribing Information; 3: Analysource: Lowest annual maintenance WAC, TG Therapeutics data on file 4: TG internal analysis.

2026 Commercial Priorities Driving the Next Phase of Growth

Expand HCP Engagement + **Amplify Patient Awareness** = **Drive Market Share Gains**

Strategic field expansion
Increase reach and frequency with high-opportunity HCPs

Scale patient initiatives across television and digital channels to further activate patients

Optimize investments to maximize impact and drive depth and breadth of prescribing

Multiple Potential Launches Over Next Several Years



TG Therapeutics

1: 2029 potential future launches are aspirational and subject to successful clinical development, regulatory approval, and other factors. No clinical development timelines have been established for these indications.

Consolidated Dosing to Simplify Starting IV BRIUMVI

ENHANCE PIVOTAL STUDY

APPROVED IV BRIUMVI DOSING



95% of all BRIUMVI 1-hour infusions were completed in 1 hour without interruption in clinical trials[1]

VS

PROPOSED IV BRIUMVI DOSING



Consolidated Dosing to Eliminate Day 15 infusion

- Trial fully enrolled
- Top-line Data ~mid 2026
- Target launch 2027

1: +/- 5 minutes, data obtained from ULTIMATE trials

Develop a Self-Administered SubQ BRIUMVI

SUBQ PIVOTAL STUDY UPDATE

APPROVED IV BRIUMVI DOSING



95% of all BRIUMVI 1-hour infusions were completed in 1 hour without interruption in clinical trials[1]

VS

PROPOSED SUBQ BRIUMVI DOSING

Target Product Profile:
Self-Administered SubQ Auto-injector

- Pivotal Phase 3 Trial: >50% enrolled
- Top-line Data ~YE26/Q1 27
- Target launch 2028

TG Therapeutics

1: +/- 5 minutes, data obtained from ULTIMATE trials; SubQ – sub cutaneous

SubQ BRIUMVI—Opportunity to Significantly Increase our Total Addressable Market

Anti-CD20 U.S. Dynamic Market Share[1]



SubQ will augment current IV business, reaching a distinct patient segment

Positions TG as only company with an offering in each market, addressing HCP and patient preferences

Leverages current commercial infrastructure with minimal incremental cost

e.g. ~85% of Target HCPs are covered by current Field Force

1: Q1'25 – Q3'25 Komodo Claims; HCP= healthcare provider; SubQ= sub cutaneous

Expanding Beyond BRIUMVI in MS

BRIUMVI INDICATIONS OUTSIDE MS

BRIUMVI as a "Pipeline in a Product"

Phase 1 trial including myasthenia gravis (MG) ongoing

Other indications under evaluation

AZER-CEL IN MS & BEYOND

Allogeneic, "off-the-shelf" CD19 CAR-T

Patients with Progressive MS now dosed in Phase 1

Data targeted in 2026

Additional indications to include NMO, MG, CIDP

R&D Goals for 2026

DATA IN 2026

Announce pivotal topline data for ENHANCE trial combining Day 1 & 15 doses of IV BRIUMVI Mid-26

Present preliminary Phase 1 azer-cel data in Progressive MS in 2H 2026

Announce pivotal topline data for subcutaneous BRIUMVI (ublituximab) YE26/1Q27

NEW TRIALS IN 2026

Commence registration-directed trial for BRIUMVI in an indication outside of MS

Commence additional exploratory studies for BRIUMVI and azer-cel in autoimmune disease (outside MS)

BRIUMVI Tracking to Become a Multi-Billion Dollar MS Franchise in the U.S.

2026 FINANCIAL GUIDANCE[1]

FY 2026 TOTAL GLOBAL NET REVENUE

~$875-900M

FY 2026 BRIUMVI U.S. NET REVENUE

~$825-850M

FY 2026 "CORE" OPERATING EXPENSE TARGET

~$350M

(excluding non-cash compensation)

FY 2026 "ONE-TIME" OPERATING EXPENSE TARGET

~$100M

(includes SubQ inventory build and secondary manufacturer start-up costs)

TG Therapeutics

1All figures presented on this slide are estimates, unaudited, subject to adjustment , and provided as an approximation in advance of the Company's announcement of complete financial results. All target guidance numbers are based on TG internal estimates; FY: Full Year

TG Highlights

- BRIUMVI continues to outperform expectations, with strong YoY growth and continued commercial momentum
- The IV portion of the anti-CD20 market alone represents an estimated multibillion opportunity for BRIUMVI
- SubQ expansion significantly increases TAM and would unlock next wave of growth
- “Pipeline in product” potential for BRIUMVI in additional indications fueling further growth opportunities as well as AZER-CEL across multiple indications
- BRIUMVI patents expected into early to mid 2040’s enables execution of long-term plan
- Significant operating leverage expected to drive accelerating profitability

TG Therapeutics

NASDAQ: TGTX